PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth
Lund, Sweden, March 27, 2025 Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application covering the active ingredient in the company’s first product, pHyph, to prevent preterm birth (premature delivery) in pregnant women…
Gedea Biotech Reports Significant Results in Study for the Treatment of Bacterial Vaginosis
PRESS RELEASE Lund, Sweden, March 12, 2025 Gedea Biotech has completed a clinical study, the NEFERTITI-2 study, for the treatment of bacterial vaginosis, showing significantly better treatment outcomes with the company's vaginal tablet pHyph compared to the control group. This result forms the…
Gedea wins prestigious scale up award
On Thursday November 28th, at the Nordic Mentor Network For Entrepreneurship - NOME annual meeting in Copenhagen, we were honored to receive the Arvind Hundal Scale-up Award for “showing inspirational growth.” We are proud, humbled, and truly grateful for this recognition. Following in the…
Emilia, industrial doctoral student at Gedea and Karolinska Institutet
Emilia Lahtinen is n industrial Ph.D. student at Gedea and at Karolinska Institutet. Her project has the title Bacterial vaginosis: Understanding the impact of antibiotic and antibiotic-free treatments on the vaginal microbiome and risk of recurrence. Please meet her in this short interview.……
Anna-Karin Areskog strengthens the team
Gedea has recently strengthened its team by hiring Anna-Karin Areskog as QA Director. Anna-Karin has been a consultant with the company since April 2023 and is now a permanent employee. In her new role, she will focus on the CE marking of pHyph and initiate the commercial-scale production of…
Gedea´s share issue oversubscribed by 54%
Gedea Biotech AB carried out a rights issue of SEK 24.3 million during October. The interest from both existing owners and new investors exceeded the board’s mandate, and an extraordinary general meeting resolved a directed issue to include the oversubscription of SEK 13 million. In total, Gedea…
Per-Ola Forsberg new CFO at Gedea
We are pleased to announce that Per-Ola Forsberg has been appointed as the new CFO of Gedea since April 20th. Per-Ola holds a degree in business adminsitration from Lund University and has over 25 years of experience in the life science industry. His previous roles include CFO positions at Pharmiva…
Gedea Biotech selected for prestigious grant funding from the European Innovation Council, EIC
Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of pHyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the development of pHyph, bringing this treatment…
The Swedish femtech company Gedea Biotech completes important clinical trial on vaginal fungal infection
The Swedish femtech company Gedea Biotech, which is developing an antibiotic-free treatment for vaginal infections, today announced that all patients in the EpHect study have been included and commenced treatment with pHyph. Results from the study are expected in the second quarter of this year.